Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2022-12-28 Board/Management Inform…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Rättelse: Hansa Biopharmas valberedning utsedd
Board/Management Information Classification · 99% confidence The document is a press release ("PRESSMEDDELANDE") announcing the composition of the Nomination Committee ("valberedning") for the upcoming Annual General Meeting (AGM) in 2023. It details who the representatives are and outlines the committee's responsibilities, which include proposing board members and remuneration for the AGM. This type of announcement, focusing on the structure and process leading up to the AGM, is closely related to AGM procedures. However, none of the specific codes perfectly match 'Nomination Committee Announcement'. 1. AGM-R (AGM Information): This usually covers presentations or materials *from* the AGM, not the pre-meeting committee formation. 2. DEF 14A (Remuneration Information): This is too specific to executive pay, although remuneration is part of the committee's scope. 3. RNS (Regulatory Filings): This is a general regulatory announcement. Given the content is specifically about the committee responsible for proposing items for the Annual General Meeting (AGM), it is most closely related to the AGM process. Since there is no specific code for 'Nomination Committee Announcement', and this is a formal corporate announcement regarding governance leading up to the AGM, it fits best under the general umbrella of AGM-related materials or as a general Regulatory Filing (RNS). Since the content directly relates to the governance structure preceding the AGM, AGM-R is a plausible fit, but RNS is safer for general corporate announcements not covered elsewhere. However, the core subject is the 'valberedning' (Nomination Committee) which directly feeds into the AGM agenda. In many classification schemes, pre-AGM governance announcements fall under the AGM category or a governance category. Since CGR is for internal rules/board structure and this is an announcement about a specific AGM preparatory body, AGM-R is chosen as the most contextually relevant category, as it pertains directly to the upcoming shareholder meeting's setup. The document is short and is an announcement, but it is announcing a specific corporate governance body, not just the publication of a larger report (which would favor RPA/RNS). I will classify it as AGM-R due to the direct link to the Annual General Meeting preparation.
2022-12-28 Swedish
Correction: Hansa Biopharma Nomination Committee formed
Board/Management Information Classification · 99% confidence The document is a press release announcing the formation and composition of the Nomination Committee, referencing decisions made at the previous Annual General Meeting (AGM) and stating that proposals for the upcoming AGM 2023 will be presented in the notice for that meeting. It discusses the function of the committee, which relates to board elections and fees, which are governance matters. While it mentions the AGM, the core content is an announcement about the committee structure, not the AGM materials themselves (AGM-R) or a proxy statement (DEF 14A/PSI). It is a specific announcement regarding corporate governance structure and board-related processes. This fits best under Governance Information (CGR), as it details internal rules/structure related to board appointments, although it is presented as a press release. Given the options, CGR is the most appropriate fit for detailed governance structure announcements outside of formal proxy filings.
2022-12-28 English
Hansa Biopharmas valberedning utsedd
AGM Information Classification · 99% confidence The document is a press release ("PRESSMEDDELANDE") announcing the formation and composition of the Nomination Committee ("valberedning") for Hansa Biopharma. The committee's purpose is explicitly stated: to prepare proposals for the upcoming Annual General Meeting (AGM) regarding board members, remuneration, and auditors. This announcement directly relates to the governance and preparation for the AGM, specifically concerning the election process. While it is related to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is an announcement about the governance structure leading up to the meeting. Since the core topic is the composition of the body responsible for nominating directors and setting the stage for shareholder votes, it falls closest to general Governance Information (CGR) or potentially a specific announcement related to the AGM process. Given the specific focus on the nomination committee's formation and duties, which are key governance functions, CGR is a strong fit. However, since the text explicitly mentions the committee's proposals will be presented at the 'årsstämman' (AGM), and the formation of this committee is a prerequisite for the AGM's election process, it is a specific governance announcement. Since there isn't a specific code for 'Nomination Committee Announcement', and it deals with board composition and shareholder voting preparation, it is best classified as Governance Information (CGR). The document length is short (2441 chars), but it is a substantive announcement, not just a notice that a report is available (RPA/RNS).
2022-12-23 Swedish
Hansa Biopharma Nomination Committee formed
Board/Management Information Classification · 99% confidence The document is a press release announcing the formation and composition of the Nomination Committee, referencing principles adopted by the Annual General Meeting (AGM) and stating that the committee's proposals will be presented in the notice for the AGM 2023. This content relates directly to the governance structure and preparation for the AGM, specifically concerning board elections and fees. While it mentions the AGM, it is not the AGM presentation itself (AGM-R), nor is it a proxy statement (DEF 14A/PSI). It is an announcement regarding the governance body responsible for nominating directors, which falls under Board/Management Information (MANG) or Governance Information (CGR). Given the focus on the composition of the committee responsible for board nominations, MANG is a strong fit, as it deals with management/board structure changes/updates. However, since the committee's function is explicitly defined by AGM rules and prepares proposals for the AGM regarding board elections, it is fundamentally a governance announcement. CGR (Governance Information) is defined as detailing internal rules, board structure, and governance practices. This announcement details the structure of a key governance body (Nomination Committee). Since MANG is specifically for changes in the board or senior management, and this is about the committee that *nominates* them, CGR is the most precise fit for detailing the structure of a key governance mechanism.
2022-12-23 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in the holding of an investor, Redmile Group, LLC, in Hansa Biopharma AB. It explicitly shows the 'Before the transaction' and 'After the transaction' share and voting rights figures, including the resulting percentage (20.6754%). The structure, focusing on 'major shareholding notification' and detailing the resulting distribution of total holdings, strongly indicates a filing related to significant ownership changes. This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2022-12-16 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding percentage for Hansa Biopharma AB, specifically noting that a corporate action (emission of new shares) caused their ownership percentage to decrease and fall below the 5% notification limit. The structure includes 'Issuer', 'Holder', 'Instrument', 'Before the transaction', 'After the transaction', and 'Resulting distribution of total holdings', which are characteristic of a major shareholding notification. The text explicitly mentions 'Reason for major shareholding notification Corporate action' and reports the new percentage (4.70667%). This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (3678 chars), but the content is the notification itself, not an announcement of a report.
2022-12-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.